Demo Data from EDBT 2026 / reviewers in the wild / expert
Alexey K. Shaytan
dblp:09/7927
· DBLP profile ↗
2ranked-venue papers
0as first author
2since 2021 · last 2026
—ORCID · none
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 2 · 2 since 2021
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 75% Medical and health informatics · 25% |
Topics — the 4 heaviest of 5, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Medical and health informatics
drug development |
0.9 | 1 | 2025 | AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025 |
Bioinformatics and computational biology › drug discovery
drug repositioning |
0.9 | 1 | 2025 | AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025 |
Bioinformatics and computational biology › drug discovery
drug response prediction |
0.9 | 1 | 2025 | AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025 |
Bioinformatics and computational biology › molecular informatics
molecular design |
0.9 | 1 | 2025 | AI in drug development: advances in response, combination therapy, repositioning, and molecular design · Sci. China Inf. Sci. 2025 |
Methods — techniques the papers use, named apart from their topics
artificial intelligence · 0.9
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2026 | DSCA-HLAII: A dual-stream cross-attention model for predicting peptide-HLA class II interaction and presentationabstractMOTIVATION: The interaction between peptides and human leukocyte antigen class II (HLA-II) molecules plays a pivotal role in adaptive immune responses, as HLA-II mediates the recognition of exogenous antigens and initiates T cell activation through peptide presentation. Accurate prediction of peptide-HLA-II binding serves as a cornerstone for deciphering cellular immune responses, and is essential for guiding the optimization of antibody therapeutics. Researchers have developed several computational approaches to identify peptide-HLA-II interaction and presentation. However, most computational approaches exhibit inconsistent predictive performance, poor generalization ability and limited biological interpretability. RESULTS: In this study, we present DSCA-HLAII, a novel predictive framework for peptide-HLA-II interactions and presentation based on a dual-stream cross-attention architecture. The framework proposes a dual-stream cross-attention (DSCA) mechanism to integrate pre-trained semantic embedding ESMC with sequence-level ONE-HOT features. The DSCA mechanism effectively models the interaction dynamics between peptides and HLA-II molecules, enabling the precise identification of key binding sites. Experimental results demonstrate that DSCA-HLAII consistently surpasses existing state-of-the-art approaches, demonstrating high accuracy and robustness in predicting peptide-HLA-II interactions and presentation. We further demonstrate the capability of DSCA-HLAII for predicting peptide binding cores and assessing antibody immunogenicity, which is expected to advance artificial intelligence-based peptide drug discovery. Shutao Chen, Alexey K. Shaytan, Youyu Wang |
PLoS Comput. Biol. | 4 |
| 2025 | AI in drug development: advances in response, combination therapy, repositioning, and molecular design
Ren Qi, Shujia Liu, Xingqi Hui, Alexey K. Shaytan |
Sci. China Inf. Sci. | 4 |